What Is USP/EP Grade Nicotine? Purity Standards Explained

The difference between 95% and 99.5% nicotine purity is not 4.5 percentage points of quality. It is the difference between an industrial feedstock and a pharmaceutical ingredient. If you are putting nicotine into a product that touches a human body, you need to understand what USP/EP grade means and why it matters.

What USP and EP Actually Are

USP stands for United States Pharmacopeia. EP stands for European Pharmacopoeia. Both are official compendia of drug quality standards maintained by independent scientific bodies. The USP is published by the United States Pharmacopeial Convention, a nonprofit organization that has been setting pharmaceutical quality standards since 1820. The EP is maintained by the European Directorate for the Quality of Medicines (EDQM) under the Council of Europe.

When nicotine carries the "USP/EP grade" label, it means the product has been manufactured and tested against the monograph specifications in both references. The nicotine monograph in each pharmacopoeia defines specific identity, purity, and quality parameters that the substance must meet. These specifications were developed based on toxicological data, clinical requirements, and analytical capabilities, not marketing considerations.

These are not marketing terms. They are legally meaningful designations backed by specific, measurable requirements. In the United States, a product labeled USP grade that does not meet the monograph specification is considered adulterated under the Federal Food, Drug, and Cosmetic Act. In Europe, EP compliance carries similar regulatory weight. Misrepresenting compliance is not just bad practice. It carries legal consequences.

The Spec Sheet

These are the parameters a nicotine specification has to cover. Some are set by the monographs themselves, in the USP Nicotine monograph in USP-NF and in Ph. Eur. monograph 1452 published by the EDQM through Ph. Eur. online; others come from general chapters or from the ICH guidelines the pharmacopoeias defer to. Apart from the USP definition line, neither monograph text is quotable from a public source, so where a limit sits behind the subscription this list says what to require of your supplier instead of printing a figure we cannot stand behind.

• Nicotine content: the two pharmacopoeias do not set the same window. The USP Nicotine monograph requires not less than 98.0% and not more than 102.0% of nicotine, calculated on the anhydrous basis. Ph. Eur. monograph 1452 requires 99.0% to 101.0% on the same basis, which is half as wide and sits entirely inside the USP range. The implication runs one way: material that meets the Ph. Eur. content limit meets the USP one, while a batch at 98.4% anhydrous is compliant USP nicotine and out of specification in Europe. Note two further things. There is an upper limit as well as a lower one, so a high result points to a measurement problem rather than to exceptional material. And the basis is anhydrous, not dried: the result is corrected for the water the sample contains, because nicotine is a hygroscopic liquid that cannot be dried to constant weight. The commonly quoted 99.5%+ is not the monograph limit for either pharmacopoeia. It is a supplier specification set above both compendial floors so that ordinary batch-to-batch variation still clears them with margin.
• Optical rotation: nicotine from tobacco is S-(-)-nicotine and is strongly levorotatory, which makes a rotation measurement the cheapest screen there is for racemic synthetic material, close to optically inactive as it is. It will not detect blending with enantiopure synthetic S-nicotine, which is optically indistinguishable from the tobacco-derived molecule and needs a separate analysis. The acceptance ranges are in the subscription text, so require the certificate to print the measured value with the solvent and the concentration behind it, and to name the chapter that produced it, rather than the word "complies". A rotation figure quoted with no dilution attached is the physical constant of the neat liquid, not evidence of compendial compliance.
• Elemental impurities: neither nicotine monograph contains element-specific numeric limits any more. USP retired general chapter 231 (Heavy Metals) with effect from 1 January 2018 in favour of chapters 232 and 233; the Ph. Eur. deleted the 2.4.8 heavy metals test from monographs on substances for pharmaceutical use from the 9th Edition and moved to 5.20 and 2.4.20. Both now follow ICH Q3D, which sets permitted daily exposures in micrograms per day and varies them by route: 5 µg/day for lead and for cadmium, 15 for arsenic, 30 for mercury by the oral route. Those become concentration limits only once a daily dose is fixed. Q3D's Option 1 table does that at an assumed 10 gram daily intake, giving 0.5 µg/g for lead and cadmium, 1.5 for arsenic and 3 for mercury. Testing is by ICP-MS. Tobacco is a known bioaccumulator of soil metals, so what belongs on the COA is a measured value per element with the method named, plus the supplier's elemental impurity risk assessment, not a bare pass or fail against a ppm number with no route attached.
• Residual solvents: controlled against the ICH Q3C limits through general chapters that apply across substances for pharmaceutical use rather than through the nicotine monograph itself: USP chapter 467, and Ph. Eur. 5.4 with the gas chromatographic method in 2.4.24. Extraction and purification of nicotine from tobacco involves solvents, and traces can remain. Q3C classifies solvents by toxicity: Class 1 (benzene, carbon tetrachloride) should not be used, Class 2 (hexane, dichloromethane) carry concentration limits, Class 3 (ethanol, acetone) are low-toxicity. The familiar Class 2 figures of 290 ppm for hexane and 600 ppm for dichloromethane are Option 1 values derived from daily exposures of 2.9 mg and 6.0 mg on a 10 gram daily intake assumption, so they move if your daily dose does.
• Water content: water is not a side issue for a hygroscopic liquid. Both monographs express the assay on the anhydrous basis, which means a water determination sits behind the assay number by definition; without one there is no anhydrous-basis result to report. Water also affects stability and accurate dosing, and excess moisture accelerates oxidation. Karl Fischer titration is the appropriate method because it measures water specifically, unlike loss-on-drying, which a volatile impurity can confound. The maximum each pharmacopoeia permits is in the subscription text, so require the COA to print the measured water figure and the chapter that produced it, next to the assay it was used to correct.
• Appearance: nicotine is not a water-white liquid and it does not lack a smell. NIOSH describes it as a pale-yellow to dark-brown liquid with a fish-like odor when warm, and high-purity freebase base is pale yellow to colorless rather than water-clear. Whichever color criterion your monograph applies, the comparison it prescribes is in the subscription text, so take the formal limit from the COA and the chapter it names. What does carry across is the direction of change: color development in storage points to oxidative degradation or to impurities that survived purification, which makes color a useful informal check between formal tests. A datasheet describing the material as water-clear and free of odor is describing something other than nicotine.
• Microbial quality: a microbial limit on a nicotine COA does not come from the same place the assay does, and the distinction matters more than it looks. USP chapters 61 and 62 are the enumeration and specified-organism methods. The acceptance criteria sit in USP chapter 1111, which sets a total aerobic microbial count of 10^3 CFU/g and a total combined yeasts and molds count of 10^2 CFU/g for substances for pharmaceutical use, then tightens at the finished dosage form. It is a PDG-harmonized chapter under code Q-05c, coordinated by the European Pharmacopoeia, so the same criteria apply on both sides under their own chapter numbers. Those criteria are written against a dosage form and a route of administration rather than against an ingredient, so a limit that is right for one route is not automatically right for another. If a COA quotes a microbial limit, ask which chapter and which table it was written against before you take it to mean what you assumed.

For a deeper look at how the two monographs differ from each other, parameter by parameter, see our USP vs. EP comparison.

Why the Standards Exist in Two Versions

USP and EP monographs for nicotine overlap substantially but are not identical. The differences reflect different regulatory philosophies and testing traditions between the US and European systems.

They do not even agree on the headline number. USP sets nicotine content at 98.0% to 102.0% on the anhydrous basis and the Ph. Eur. sets it at 99.0% to 101.0% on the same basis, so the European window is the tighter one and USP content compliance does not imply Ph. Eur. content compliance. Each pharmacopoeia then prescribes its own identification, related substances, water and residual solvent procedures under its own chapters, with its own official reference materials, which is why a result generated under one monograph's method is not automatically evidence of compliance with the other. On elemental impurities the two have converged, both now deferring to ICH Q3D rather than to their own legacy heavy metals tests.

For manufacturers selling into both markets, the practical approach is to test against the stricter of the two criteria for each parameter, and to run both prescribed methods where the methods differ rather than assuming one result substitutes for the other. Most pure nicotine produced for international markets is tested to meet both monographs.

Why Your Customers Can Tell the Difference

For e-liquid manufacturers, impurities are not abstract. They show up as harshness, peppery off-notes, and color drift in finished products. A batch of e-liquid that turns amber on the shelf is not an aging problem. It is a nicotine purity problem. The minor alkaloids present in sub-pharmaceutical-grade nicotine (nornicotine, myosmine, cotinine, and others) oxidize at different rates than nicotine itself, producing colored compounds that darken the liquid over time. Because they oxidise on a different timescale to nicotine, they can produce visible color change in a finished liquid that was water-clear when it was filled.

Flavor stability is another casualty of impure nicotine. Minor alkaloid impurities are chemically reactive in their own right, and they vary in both identity and concentration between batches of sub-pharmaceutical-grade material. That variability is the problem: a flavor system tuned against one batch is being tuned against a slightly different set of reactants in the next. Moving to material certified against a monograph does not make a formulation taste better by itself. What it does is remove the nicotine from the list of variables, so the differences you observe between batches of finished product are attributable to something you control.

For nicotine pouch manufacturers, purity determines delivery consistency. Minor alkaloid contaminants (nornicotine, anabasine, anatabine) alter absorption kinetics through the oral mucosa. These compounds have different pKa values and lipophilicity than nicotine, which means they cross biological membranes at different rates. The result is unpredictable nicotine delivery that varies from batch to batch. Your lab might not catch the variance in chemical testing. Your consumers will notice it as inconsistent satisfaction.

For NRT pharmaceutical companies, the question is simpler. USP/EP compliance is a regulatory requirement. No compliant nicotine, no product approval. The pharmaceutical supply chain has no tolerance for "close enough." Every batch must meet spec, every COA must reference the monograph, and every deviation must be investigated and documented.

How to Verify the Claim

Every batch of pure nicotine should ship with a Certificate of Analysis from an accredited laboratory. The COA should cover every parameter on your specification: purity, heavy metals, residual solvents, water content, microbial testing.

There are specific things to look for on a COA that separate genuine documentation from window dressing:

Accreditation marks. The testing laboratory should hold ISO 17025 accreditation with nicotine and related alkaloids in their scope of accreditation. A lab that is ISO 17025 accredited for water testing but not pharmaceutical alkaloid analysis is not providing accredited results for nicotine purity.

Test method references. Each result should cite the specific USP or EP method used. "Purity: 99.5%" without a method reference is not a pharmacopoeial result. It is a number on a page.

Batch-specific data. The COA should reference a specific batch or lot number, manufacturing date, and expiry date. Generic COAs that apply to "all production" are worthless for regulatory purposes and suggest the supplier is not performing batch-level testing.

Related substances profile. Beyond the total purity number, a complete COA identifies and quantifies the individual minor alkaloids and degradants rather than rolling them into a sum. The compounds that matter for nicotine are the ones that travel with it out of the leaf or form from it in storage: anatabine, beta-nicotyrine, cotinine, myosmine, nicotine N-oxide, nornicotine and anabasine. The USP monograph treats them as named entities rather than as an anonymous total, and that much is publicly visible: its reference standards list runs Nicotine Bitartrate Dihydrate RS plus Nicotine Related Compound A through Nicotine Related Compound G. The per-impurity limits themselves are inside the subscription text on both sides, so require each compound reported as a measured value against whatever limit the COA names, not as the word "complies". That profile is often more informative than the headline purity number, because it shows how effective the purification actually was and whether the material has started to oxidise in storage.

If a supplier cannot produce a current, batch-specific COA on request, that tells you something. If the COA lacks test method references or accreditation details, that tells you more.

The 95% vs. 99.5% Gap

Nicotine alkaloid at 95% purity contains roughly 5% of other tobacco alkaloids, plant extracts, and processing byproducts. It is amber-brown, has a strong tobacco odor, and is suitable as a feedstock for further refinement. It is not suitable for direct use in consumer products.

That 5% is not inert filler. It is a complex mixture of biologically active compounds. Nornicotine, the most common minor tobacco alkaloid, can form tobacco-specific nitrosamines (TSNAs) under certain conditions. Anabasine and anatabine have their own pharmacological profiles that differ from nicotine. Myosmine is found in other plants besides tobacco and has been studied for its own biological effects. None of these belong in a product where the intended active ingredient is nicotine alone.

At 99.5%, multi-stage distillation has removed virtually everything that is not nicotine. The result is a pale yellow to colorless liquid, far lighter than the crude alkaloid and far weaker in smell, though it never loses its odor entirely: NIOSH describes nicotine as a pale-yellow to dark-brown liquid with a fish-like odor when warm. That is the baseline for any product where nicotine contacts a consumer.

The purification process that bridges this gap typically involves multiple distillation stages under reduced pressure (to prevent thermal degradation), followed by additional purification steps such as molecular distillation or selective crystallization of salts. Each stage reduces impurity levels but also reduces yield, which is why pharmaceutical-grade nicotine costs more per kilogram than crude alkaloid extract. The price difference reflects real processing costs, not just a premium for a label.

Storage and Stability

Even USP/EP grade nicotine will degrade if handled improperly. Nicotine is sensitive to three things: oxygen, light, and heat. Exposure to any of these triggers oxidation reactions that produce colored degradation products and reduce potency.

Storage is the one part of the specification that transfers to you the moment the drum is delivered, so it is worth being precise about where the requirement comes from. Both monographs carry packaging and storage directions and both sit in the subscription text, so take the binding wording from the edition you are certifying against rather than from a supplier datasheet that paraphrases it. The practical shape of it follows from the chemistry above and is not controversial: inert atmosphere, opaque container, cool and dry, and colder storage is common practice for long-held stock. Write your incoming goods procedure against the compendial wording once you have it in front of you. Suppliers who ship nicotine in clear containers or without temperature control in transit are undermining the purity they certified whatever the monograph says.

Stability data should be part of the documentation package from your supplier. Accelerated stability studies (40C/75% relative humidity for 6 months) and real-time stability data tell you how long the material maintains spec under defined conditions. Without this data, you are guessing at shelf life, and guessing is not a quality strategy.

Nicotine Salts and Dilutions: How Purity Standards Apply

USP/EP standards apply to freebase nicotine, but the purity of the starting material directly affects derivative products. Nicotine salts (benzoate, bitartrate, salicylate, and others) are synthesized from freebase nicotine, so impurities in the starting material carry through to the salt form. A nicotine benzoate made from 97% freebase nicotine will contain the same impurity profile as its starting material, just at proportionally lower absolute concentrations due to the added mass of the salt-forming acid.

Nicotine dilutions in PG or VG carriers present a similar principle. Diluting impure nicotine does not remove impurities. It dilutes them. For e-liquid manufacturers working with 100mg/mL nicotine bases, starting with USP/EP grade freebase ensures that impurity concentrations in the dilution remain well below levels that affect flavor or stability.

If Someone Offers You "Pharmaceutical Grade" at a Suspiciously Low Price

Ask for the COA and check the numbers. Pharmaceutical-grade nicotine requires multi-stage purification, accredited testing, and quality systems that cost real money to maintain, and those costs do not vary much between competent producers. So when a quote comes in well below what everyone else in the market is quoting, the gap has to be coming from somewhere. Usually it is one of three places: sub-specification material shipped with a compliant-looking certificate, a genuine but temporary cross-subsidy from another business line, or savings taken out of the testing and documentation programme, which is the one you will not notice until a regulator or a customer audits your supply chain.

The useful question is not "why is this cheap" but "which of those three is it", because only one of them is survivable. Ask what the price includes: how many batches of stability data, which tests are run in-house against which are sent to an accredited lab, and whether the quoted price assumes you accept a template certificate.

The lowest-risk approach is to verify independently. Request a sample, send it to your own accredited lab, and compare the results to the supplier's COA. If the numbers match, you have a qualified supplier. If they do not, you have avoided a problem.

Frequently Asked Questions